Investment analysts at HC Wainwright cut their FY2028 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects ...

Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...

H.C. Wainwright analyst Edward White maintained a Hold rating on Avalo Therapeutics (AVTX – Research Report) today. The company’s shares opened ...

H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report.

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Fireside chat Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC. March 27 at 08.00am EST ...

On Wednesday, H.C. Wainwright reiterated a Neutral rating on Cassava Sciences (NASDAQ:SAVA), following the company’s announcement of its financial and operational results for the fiscal year that ...